Latest News

Start of the Phase 2 Clinical Study of the Vaxine-originated COVID-19 vaccine in Iran

On May 30th, CinnaGen company announced the start of Phase 2 human clinical trial of its potential COVID-19 vaccine. This vaccine candidate was originally developed by Vaxine Pty Ltd under the brand name COVAX-19 and is a collaboration between CinnaGen and Vaxine. As of June 1st, all the 400 planned volunteers were enrolled in the […]

“SpikoGen®”, a joint venture between Vaxine and CinnaGen

In a new cooperation agreement, Phases 2 and 3 clinical trials of the Vaxine’s monovalent recombinant COVID-19 vaccine will be initiated in Iran in the coming weeks. If these studies are successful, this Australian vaccine will be produced under the brand name “SpikoGen®” by CinnaGen Company and will be rolled out in Iran.

Early Promising Data From the Phase 1 Clinical Trial of the Vaxine’s COVID-19 Vaccine

The Phase 1 trial of COVAX-19®, the Australian COVID-19 vaccine developed by Vaxine Pty Ltd, was independently conducted by the PARC clinical trial team, a University of Adelaide based research group. The study was started on June 30, 2020, at the Royal Adelaide Hospital and included 40 healthy participants aged between 18 and 65 years. […]